OncoMatch/Clinical Trials/NCT07183189

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Is NCT07183189 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A2009 ; Aumolertinib and Aumolertinib for non-small cell lung cancer.

Phase 3RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07183189Data as of May 2026

Treatment: SHR-A2009 ; Aumolertinib · Aumolertinib — This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Kidney function

Liver function

Adequate bone marrow and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify